AU2020267142B2 — Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms

USPTO Abstract

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myeloproliferative disorders, such as Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having myeloproliferative disorder s, such as ET. WO 20141088785 PCT/US2013/070437 1/9 Figure A 160.00 140.00 --------------------------------------------------------------------------------------------------- 140.00- 840.00 - - - - - - - - - - - - - - - - - - ----------- 00.00 x "Fu 40.00 ------------------ 20.00 - 0.00 Day Day Day Day Day Day Day Day Day Day Day 0 1 2 3 4 5 6 7 10 14 17 Imetelstat 0.9 uM 422.001837855 * Imetelstat 1.875 uM200 2.7 3.22 00 74421.5630.755550 11504573970 SImetelstat 3.75 uM 2.00 1.56 2.56 5.00 8.11 16.44 2700383310103975600 E Imetelstat 7.5 uM 2.00 1.44 2.00 4.56,10.44 15.4426.7541.00196.50 46.33 52.30 E lmetelstat 15 uM 2.00 1.89 3.00 4.78 7.56 15.5625.20 3933107.5 36.3335.70 z Standard Control 2.00 2.00 2.44 4.33 9.22 15.3325.33 56001141.0 18.83 38.70 S1 5olvent Control '2.0042563.33 4.57 11.22''53,124.317O2.~3,0